In vitro allogeneic NK cell responses against HIV-1 patient-derived CD4+ T cells as a function of KIR/HLA genotype
| NK cells . | CD4+ T cells . | Donor KIR/HLA . | Patient HLA . | Donor/patient KIR/HLA . | CD4+ T-cell killing . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Blood donor . | Patient . | HIV-1 load* . | KIR† . | KIR2DL . | HLA-C . | HLA-C . | Missing self‡ . | 3DS1/Bw4 . | 7-AAD (%) . | Annexin V (%) . |
| BFC01 | ITM01 | 4.52 | AA | 2DL1 + 2DL3/3 | C2/C2 | C1/C1 | 2DL1 | Yes | 12.65 | 3.85 |
| BFC08 | ITM21 | < 1.30 | AA | 2DL1 + 2DL3/3 | C1/C1 | C2/C2 | 2DL3 | Yes | 12.17 | 12.87 |
| BFC01 | ITM03 | < 1.30 | AA | 2DL1 + 2DL3/3 | C2/C2 | C1/C1 | 2DL1 | Yes | 11.04 | 4.87 |
| BFC05 | ITM13 | 5.43 | BB | 2DL1 + 2DL2/2 | C1/C2 | C2/C2 | 2DL2 | Yes | 5.38 | 7.05 |
| BFC06 | ITM15 | < 1.30 | BB | 2DL1 + 2DL2/2 | C1/C2 | C1/C1 | 2DL1 | No | 5.21 | 6.41 |
| BFC05 | ITM17 | < 1.30 | BB | 2DL1 + 2DL2/2 | C1/C2 | C2/C2 | 2DL2 | Yes | 4.10 | 4.93 |
| BFC07 | ITM19 | < 1.30 | AB | 2DL1 + 2DL2/3 | C1/C2 | C2/C2 | 2DL2/3 | No | 3.73 | 4.48 |
| BFC06 | ITM18 | < 1.30 | BB | 2DL1 + 2DL2/2 | C1/C2 | C1/C2 | None | No | 2.52 | 2.69 |
| BFC03 | ITM12 | < 1.30 | AA | 2DL1 + 2DL3/3 | C2/C2 | C1/C2 | None | No | 0.53 | 1.22 |
| BFC03 | ITM09 | 5.53 | AA | 2DL1 + 2DL3/3 | C2/C2 | C1/C2 | None | No | 0.16 | 0 |
| BFC08 | ITM24 | 4.64 | AA | 2DL1 + 2DL3/3 | C1/C1 | C1/C2 | None | No | 0 | 0 |
| BFC07 | ITM23 | 4.71 | AB | 2DL1 + 2DL2/3 | C1/C2 | C1/C2 | None | No | 0 | 0 |
| NK cells . | CD4+ T cells . | Donor KIR/HLA . | Patient HLA . | Donor/patient KIR/HLA . | CD4+ T-cell killing . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Blood donor . | Patient . | HIV-1 load* . | KIR† . | KIR2DL . | HLA-C . | HLA-C . | Missing self‡ . | 3DS1/Bw4 . | 7-AAD (%) . | Annexin V (%) . |
| BFC01 | ITM01 | 4.52 | AA | 2DL1 + 2DL3/3 | C2/C2 | C1/C1 | 2DL1 | Yes | 12.65 | 3.85 |
| BFC08 | ITM21 | < 1.30 | AA | 2DL1 + 2DL3/3 | C1/C1 | C2/C2 | 2DL3 | Yes | 12.17 | 12.87 |
| BFC01 | ITM03 | < 1.30 | AA | 2DL1 + 2DL3/3 | C2/C2 | C1/C1 | 2DL1 | Yes | 11.04 | 4.87 |
| BFC05 | ITM13 | 5.43 | BB | 2DL1 + 2DL2/2 | C1/C2 | C2/C2 | 2DL2 | Yes | 5.38 | 7.05 |
| BFC06 | ITM15 | < 1.30 | BB | 2DL1 + 2DL2/2 | C1/C2 | C1/C1 | 2DL1 | No | 5.21 | 6.41 |
| BFC05 | ITM17 | < 1.30 | BB | 2DL1 + 2DL2/2 | C1/C2 | C2/C2 | 2DL2 | Yes | 4.10 | 4.93 |
| BFC07 | ITM19 | < 1.30 | AB | 2DL1 + 2DL2/3 | C1/C2 | C2/C2 | 2DL2/3 | No | 3.73 | 4.48 |
| BFC06 | ITM18 | < 1.30 | BB | 2DL1 + 2DL2/2 | C1/C2 | C1/C2 | None | No | 2.52 | 2.69 |
| BFC03 | ITM12 | < 1.30 | AA | 2DL1 + 2DL3/3 | C2/C2 | C1/C2 | None | No | 0.53 | 1.22 |
| BFC03 | ITM09 | 5.53 | AA | 2DL1 + 2DL3/3 | C2/C2 | C1/C2 | None | No | 0.16 | 0 |
| BFC08 | ITM24 | 4.64 | AA | 2DL1 + 2DL3/3 | C1/C1 | C1/C2 | None | No | 0 | 0 |
| BFC07 | ITM23 | 4.71 | AB | 2DL1 + 2DL2/3 | C1/C2 | C1/C2 | None | No | 0 | 0 |
Every healthy blood donor is assessed against 2 different HIV-1 patients. The data are sorted in descending order based on CD4+ T cell killing (% 7-AAD). There were no missing self combinations at the level of KIR3DL1/HLA-Bw4.
Data are log10 HIV-1 RNA copies/mL. All patients with undetectable (< 1.30 log10 copies/mL) are under antiretroviral therapy, all patients with detectable (> 1.30 log10 copies/mL) are therapy-naive.
Centromeric KIR genotypes.
Defined as the blood donor inhibitory KIRs that recognized an HLA allotype present in the blood donor but that was lacking in the HIV-1 patient.11